A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

OSI Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

NSCLC

Treatments

Drug: Tarceva

Study type

Interventional

Funder types

Industry

Identifiers

NCT00294736

OSI-774-107

2005-003883-46 (EudraCT Number)

Details and patient eligibility

About

This is a multicenter, open-label, randomized phase 1 study of escalating doses of Tarceva in patients with advanced NSCLC who currently smoke.

Part I will establish the maximum tolerated dose (MTD) of Tarceva in current smokers.

In Part II, patients will be randomized 1:1 to two treatment groups: Arm A (Tarceva MTD established in Part I) and Arm B (150 mg Tarceva daily). Patients in both arms will be treated for two weeks and then have pharmacokinetic samples collected on day 14. Part II is open as of Nov-2006.

Enrollment

57 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed diagnosis of stage IIIB/IV NSCLC;
Must have received 1 or 2 prior chemotherapy regimens for advanced NSCLC and now have progressive disease;
Must have recovered from any treatment-related toxicities prior to registration, except for alopecia, grade 1 fatigue, or grade 1 neurotoxicity;
A current cigarette smoker (minimum of 10 cigarettes per day for >= 1 year and have a positive test for cotinine) despite advice and support to quit;
Age >= 18 years;
ECOG PS 0-1 and predicted life expectancy >= 12 weeks;
Previous surgery is permitted provided that wound healing has occurred prior to registration;
Adequate hematopoietic, hepatic and renal function defined as follows: ANC >= 1.5 x 10^9/L, platelets >= 100 x 10^9/L, bilirubin <= 1.5 x ULN, ALT <= 2.5 x ULN (or 5 x ULN in case of liver metastases), creatinine <= 1.5 x ULN;
No prior treatment with Tarceva or gefitinib (or other drug with significant activity against EGFR (eg, cetuximab and/or ZD6474));
Patients with reproductive potential must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test within 14 days prior to registration;
Accessible for repeat dosing and follow-up.

Exclusion criteria

Any concurrent anticancer cytostatic or cytotoxic chemotherapy;
Concomitant CYP3A4 or CYP1A2 inducers/inhibitors (or during 14 days prior to study) with the exception of tobacco;
Other active malignancies, unless disease-free and without cancer-specific therapy for at least the last 5 years. Basal or squamous cell skin cancers are not excluded;
Significant history of cardiac disease unless the disease is well-controlled;
Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study;
History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements; of the study or to provide informed consent.
Gastrointestinal abnormalities, including inability to take oral medication, requirement for IV alimentation, active peptic ulcer or prior surgical procedures affecting absorption;
Clinically significant ophthalmologic abnormalities;
Pregnant or breast-feeding females. Males or females not practicing effective birth control;
Symptomatic brain metastases which are not stable, require steroids, or that have required radiation within the last 28 days;
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug;